Redeye’s short comment on the new CEO appointment.
Solid sales growth at 10.4% y-o-y, all organic EBIT growth of 28% with excellent cost control Demand...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year ...
Windon Energy Group publicerade den 29 augusti 2023 bolagets delårsrapport för det andra kvartalet 2...
Umida levererade ett resultat i linje med förväntningarna i Q2.
Soft Q2, but solid volume guidance ahead New presumptive rents are up 10%, a clear positive 2023e P/...
Redeye comments on Klaria Pharma’s Q2 2023 report. Despite the recent rights issue at the end of 202...
Redeye provides its comment on Mendus’ Q2 2023 report.
Alla blickar på AKITA-studien Guards rapport för det andra kvartalet innehöll som väntat inga överra...
Fortsatt press från externa faktorer Tourns omsättning under Q2 var fortsatt pressad, drivet av att ...
Q1 – ett säsongsmässigt svagt kvartal Nettoomsättningen var 29,5 mkr (42,2 mkr), -30% y/y.
Redeye is encouraged by the full recruitment of 20 patients in ATLAS-IT-05, which we discuss in this...
Soft topline, higher spending on the the sales force.
Sales continue to be affected by slowdown... ...but demand should come up in H2.
The strong start to 2023 has now made its mark in the books, with the revenues to date already surpa...
Trots ett negativt nettoresultat på 5 MSEK för det andra kvartalet 2023, fortsätter Northern CapSek ...
Equity Analyst Markus Almerud makes an update on Maha Energy after the recent developments.
Redeye provides an update following Heliospectra’s Q2’23 report.
2023e sales increased by 4%, earnings lowered by 2% Earnings forecasts beyond 2023e up by 7-17% Stro...
Läkemedelsbolaget EQL Pharma redovisade ökad nettoomsättning och oförändrad EBIT i det första kvarta...
